IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Gentamicin-Induced Renal Injury and the Promise of Polyherbal Remedies: An Integrative Review

Author: Komal R. Dange, Sachin C. Kale, Pavan Folane, Kailas R. Biyani

Department of Pharmacology

Anuradha College of Pharmacy, Chikhli Dist. Buldhana(MS) India

Corresponding Author:

Miss. Komal Rajesh Dange

ABSTRACT

Gentamicin, a widely prescribed aminoglycoside antibiotic, is highly effective against severe Gram-negative bacterial infections; however, its clinical utility is significantly limited by its nephrotoxic potential. Gentamicin-induced renal injury primarily affects proximal tubular epithelial cells and is mediated by complex, interrelated mechanisms, including excessive generation of reactive oxygen species, mitochondrial dysfunction, lysosomal phospholipidosis, release of inflammatory cytokines, and activation of apoptotic pathways. Despite dose adjustment and therapeutic drug monitoring, the incidence of gentamicin-associated nephrotoxicity remains substantial, particularly in elderly patients and those with pre-existing renal impairment or polypharmacy.

This review explores the molecular and cellular mechanisms of gentamicin-induced kidney damage and highlights recent research on Polyherbal remedies with potential nephroprotective effects. Evidence suggests that formulations containing flavonoids, phenolics, tannins, and terpenoids may protect the kidneys by enhancing antioxidant defences, reducing inflammation, maintaining cell membrane stability, and modulating proteins involved in cell death, such as Bcl-2 and caspases. Polyherbal remedies may be more effective than single-compound treatments because they target multiple pathways involved in kidney injury.

This review highlights the potential of combining traditional herbal medicine with modern nephrology research to develop safer treatments for drug-induced kidney injury. While early results are promising, challenges remain in standardizing remedies, ensuring quality, understanding pharmacokinetics, and proving clinical efficacy. Future research should focus on rigorous clinical trials to confirm the effectiveness of polyherbal remedies. These formulations may complement current therapies to prevent gentamicin-induced kidney damage and improve the safety of gentamicin use.

Keywords: Gentamicin; Nephrotoxicity; Drug-induced renal injury; Oxidative stress; Polyherbal formulations; Renal protection; Integrative medicine

1. Introduction

The kidneys remove waste and toxins from the blood and help maintain fluid balance. When kidney function is impaired, waste products and electrolytes, including potassium and magnesium, can accumulate to dangerous levels. Several drugs, such as antibiotics, Non-steroidal anti-inflammatory drugs (NSAIDs), Angiotensinogen Converting Enzyme (ACE) inhibitors, and contrast agents, are major contributors to kidney damage. An Indian study found that drug-induced acute renal failure (ARF) accounted for 20% of all ARF cases, with aminoglycosides responsible for 40% of these disorders (1). As life expectancy rises, older adults present with chronic illnesses, take multiple medications, and undergo procedures that may compromise kidney function. Drug-induced kidney disease is now a significant cause of both acute and chronic renal disorders. Its incidence is increasing due to higher medication use and easier access to over-the-counter drugs (2). Lifestyle changes have also led to more cases of diabetes and hypertension, which are the leading causes of kidney disease. According to Med India, the incidence of kidney failure has doubled in the past 15 years, with over 15 million people worldwide living with dialysis or a functioning kidney graft. In India, about 7.85 million people have chronic kidney failure, and 90% cannot afford treatment (3). As a result, the global prevalence of kidney disease continues to rise. Many medications can cause renal injury, leading to conditions such as acute renal failure and chronic nephritis.

Aminoglycoside antibiotics are widely used in clinical practice due to their effectiveness against bacteria, low rates of resistance, post-antibiotic effects, and cost-efficiency. Their poly-cationic structure leads to poor oral absorption, limited cerebrospinal fluid penetration, and rapid renal clearance (4). Gentamicin (GM), the third aminoglycoside approved for systemic use, is commonly prescribed for acute infections caused by aerobic Gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae, Enterobacter, Haemophilus influenzae, Proteus, Serratia, and Pseudomonas Aeruginosa. It is also effective against Brucella, Campylobacter, Citrobacter, Francisella, and Yersinia strains (3). GM was first isolated from Micromonospora purpurea, a Gram-positive bacterium found in aquatic and terrestrial environments (5). GM inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking initiation complex formation with mRNA, and causing translation errors that result in defective proteins. At physiological pH, GM is polycationic, highly water-soluble, minimally metabolized, and widely distributed in body tissues. GM chelates iron, and the resulting iron-GM complex promotes the generation of oxygen-derived radicals. Although gentamicin is effective for severe Gram-negative infections, it is associated with nephrotoxicity (6). Prolonged use beyond seven days can alter proximal tubular cell morphology and cause renal injury.

Aminoglycosides are filtered by the kidneys and rapidly internalized by proximal tubular cells, where they accumulate in lysosomes after interacting with cell-surface phospholipids. Gentamicin binds to negatively charged phospholipids and accumulates in lysosomes, leading to phospholipidosis by inhibiting lysosomal phospholipases and causing renal cell death (7). Nephrotoxicity is linked to gentamicin accumulation in the convoluted tubules and lysosomes of the kidney. It also promotes the formation of

reactive oxygen species (ROS), leading to oxidative stress. Experimental studies show that gentamicin increases superoxide anion, hydrogen peroxide, and hydroxyl radical production in renal cortex mitochondria (8). Inhibition of antioxidant enzyme activity is associated with gentamicin-induced acute renal failure. Gentamicin can damage the kidneys by increasing lipid peroxidation, elevating levels of inflammatory cytokines such as TNF-α and IL-6, and causing the death of proximal tubular cells. While different drugs and dosing changes have been tested, none have fully protected the kidneys. Recently, researchers have begun investigating poly-herbal formulations as potential approaches to prevent kidney injury (9).

2. Pathophysiology of Gentamicin

Gentamicin (GM) is an antibiotic that kills bacteria by crossing the cell wall and binding to ribosomes, which halts protein synthesis. In gram-negative bacteria, GM enters via porin channels, a process that depends on the electron transport chain, membrane polarization, and oxygen. Under anaerobic conditions, this entry does not occur. Once inside, GM binds to the 30S subunit and the 30S-50S interface of the ribosome, blocking protein synthesis, preventing polysome formation, and causing ribosomes to dissociate. This binding also disrupts mRNA translation, leading to errors in protein synthesis. GM further damages bacteria by increasing cell wall permeability, leading to leakage of cellular contents and cell death, likely due to the incorporation of faulty proteins into the membrane (10).

GM can cause side effects, including ototoxicity, cochlear and vestibular damage, and kidney problems. Ototoxicity is the most serious and depends on dose and treatment duration. GM accumulates in inner ear fluid and is slowly eliminated as blood levels decrease. The risk of ototoxicity rises when blood levels exceed 2 micrograms per milliliter; to reduce this risk, trough levels should remain below 1 microgram per millilitre (11). Cochlear damage usually begins at the base and progresses toward the apex, initially affecting high-frequency hearing. Because sensory cells do not regenerate, hearing loss is permanent. Early cochlear toxicity is asymptomatic and detectable only through hearing tests. Tinnitus may develop, followed by hearing loss. Discontinuing GM usually resolves tinnitus within 4 to 10 days, but hearing loss is irreversible. Vestibular toxicity may cause headache, nausea, vomiting, dizziness, nystagmus, vertigo, and balance issues. If GM is stopped at this stage, symptoms may persist for 6 to 10 weeks, with patients experiencing difficulty walking but normal sensation at rest. Recovery may take 1 to 2 years and depends on the extent of damage and the patient's age (12).

GM may also cause neuromuscular blockade by reducing acetylcholine release from motor neurons, disrupting synaptic vesicle trafficking, and decreasing muscle end plate sensitivity to acetylcholine. Although rare during standard therapeutic use, apnea and fatalities have occurred after intra-abdominal or intrathoracic administration postoperatively. Neuromuscular blockade can be partially reversed with intravenous calcium; however, neostigmine is not consistently effective (13). GM can cause nephrotoxicity even at low doses. Some of the drug is internalized by renal tubular cells through endocytosis, resulting in vacuole-lysosome fusion. This process causes lysosomal phospholipidosis and tubular cell death, which are primary contributors to kidney injury. GM is not given orally because of poor gastrointestinal absorption. It is usually administered by injection or topical application and is excreted unchanged in the urine (14). Fig 1 highlights the pathophysiology of gentamicin-induced nephrotoxicity.



Fig 1: Pathophysiology of Gentamicin-Induced Nephrotoxicity

3. Biomarkers of Nephrotoxicity

The progression of gentamicin-induced nephrotoxicity is commonly assessed through biochemical and oxidative stress biomarkers. Table 1 lists the biochemical and oxidative stress biomarkers.

Table 1: Lists the biochemical and oxidative stress biomarkers (15-16).

Category	Biomarker	Significance	Change during Toxicity
Renal Function Markers	Serum creatinine, Blood urea nitrogen (BUN), Uric acid	Reflect glomerular filtration efficiency	↑ Elevated
Tubular Damage Markers	Urinary N-acetyl-β-D-glucosaminidase (NAG), Kidney injury molecule-1 (KIM-1)	Indicate proximal tubular injury	↑ Elevated
Oxidative Stress Indicators	Malondialdehyde (MDA)	Marker of lipid peroxidation	↑ Elevated
	Reduced glutathione (GSH), Superoxide dismutase (SOD), Catalase (CAT)	Endogenous antioxidants	↓ Decreased
Inflammatory Cytokines	TNF-α, IL-6, NF-κB	Mediators of inflammation and apoptosis	↑ Elevated

Elevated levels of serum creatinine and BUN serve as primary diagnostic indicators of renal dysfunction, while reduced antioxidant enzyme levels (SOD, CAT and GSH) indicate oxidative stress involvement. Restoration of these biomarkers in experimental studies is a key indicator of the nephroprotective potential of herbal and Polyherbal therapies

4. Phytomedicine and Polyherbal Formulations in Renal Protection

4.1 Role of Medicinal Plants in Nephroprotection

Traditional medical systems such as Ayurveda, Siddha, and Traditional Chinese Medicine (TCM) have long recognized the kidney as a vital organ for maintaining systemic homeostasis, particularly in fluid balance and detoxification. These systems employ a diverse range of herbal agents—including *Boerhaavia diffusa* (Punarnava), *Tribulus terrestris* (Gokshura), *Phyllanthus emblica* (Amla), *Tinospora cordifolia* (Guduchi), and *Curcuma longa* (Turmeric)—as "Rasayana" (rejuvenative) and "Mutrakrichhara" (anti-nephrotoxic) remedies (17).

Experimental studies substantiate the nephroprotective potential of these botanicals through antioxidant, anti-inflammatory, and cytoprotective mechanisms. For instance, *Boerhaavia diffusa* exhibits free radical scavenging properties by increasing superoxide dismutase (SOD) and glutathione (GSH) activity, while *Curcuma longa* suppresses NF-κB–mediated inflammation and lipid peroxidation. Similarly, *Phyllanthus emblica* and *Tinospora cordifolia* restore renal enzyme balance and reduce tubular necrosis through their rich polyphenolic content (18).

In TCM, herbs such as *Astragalus membranaceus*, *Panax ginseng*, and *Salvia miltiorrhiza* are traditionally prescribed for chronic kidney disease (CKD) and have demonstrated modulation of oxidative stress and apoptotic pathways in experimental models. The convergence of these traditional insights with contemporary pharmacological validation underscores the potential of phytomedicine as a multi-target nephroprotective strategy (19).

Collectively, these herbal agents operate through:

- Inhibition of ROS and lipid peroxidation
- Stimulation of antioxidant enzymes (SOD, CAT, GPx)
- Suppression of inflammatory cytokines (TNF-α, IL-6)
- Preservation of mitochondrial function and membrane integrity

These findings establish a strong scientific basis for the transition from single-herb to Polyherbal formulations in renal protection (20).

4.2 Polyherbal Synergy

The concept of polyherbal synergy—a cornerstone of Ayurvedic pharmacology—posits that combining multiple herbs yields enhanced therapeutic efficacy compared to individual constituents. The phytochemical diversity within a polyherbal formulation allows simultaneous targeting of several nephrotoxic pathways, including oxidative stress, inflammation, and apoptosis (21). Each component in a polyherbal blend contributes distinct yet complementary bioactivities:

- Antioxidant herbs (e.g., *Phyllanthus emblica*, *Camellia sinensis* and *Curcuma longa*) neutralize ROS and enhance endogenous enzymatic defense.
- Anti-inflammatory agents (e.g., *Moringa oleifera*, *Hibiscus sabdariffa*, *Zingiber officinale*) downregulate cytokines like TNF-α and IL-6.
- Cytoprotective and regenerative herbs (e.g., *Tinospora cordifolia*, *Withania somnifera*) support tissue repair and mitochondrial stability (22-23).

This synergistic mechanism was demonstrated in formulations such as Neeri-KFT, a clinically studied Ayurvedic blend comprising *Boerhaavia diffusa*, *Tribulus terrestris*, and *Crataeva nurvala*, which effectively reversed gentamicin-induced nephrotoxicity by restoring renal function biomarkers and antioxidant status. Similarly, the polyherbal renal tea extract (RTE) developed by exhibited additive anti-inflammatory and antioxidant effects in experimental nephrotoxicity (24).

Beyond biochemical synergy, polyherbal formulations also reduce the toxic load of individual herbs through pharmacodynamic balancing, ensuring enhanced efficacy with minimal side effects**.** Advances in metabolomic profiling and network pharmacology further validate this concept, demonstrating that polyherbal combinations activate diverse cellular targets such as Nrf2**,** Bcl-2**,** and Caspase-3**,** thereby providing comprehensive renal protection (25). Table 2 lists medicinal plants that have been reported to protect against Gentamicin-Induced Nephrotoxicity.

Table 2. Twenty Medicinal Plants Reported to Protect Against Gentamicin-Induced Nephrotoxicity

S.No.	Scientific Name	Common Name	Major Active Compounds	Mechanism of Nephroprotection	Reference
1	*Boerhaavia diffusa*	Punarnava	Boeravinones, flavonoids	Antioxidant, anti-inflammatory	26
2	*Phyllanthus emblica*	Indian Gooseberry / Amla	Ascorbic acid, ellagic acid	Scavenges ROS, improves GSH	27
3	*Curcuma longa*	Turmeric	Curcumin	Inhibits NF-κB, reduces lipid peroxidation	28
4	*Tinospora cordifolia*	Guduchi / Giloy	Tinosporin, berberine	Immunomodulation, antioxidant	25
5	*Tribulus terrestris*	Gokshura	Saponins, protodioscin	Reduces oxidative stress and uremia	29
6	*Moringa oleifera*	Drumstick Tree	Quercetin, chlorogenic acid	Anti-inflammatory, antioxidant	26
7	*Zingiber officinale*	Ginger	Gingerols, shogaols	Increases SOD, CAT; reduces TNF-α	30
8	*Camellia sinensis*	Green Tea	Catechins, EGCG	Free radical scavenging, nephron protection	24
9	*Hibiscus sabdariffa*	Roselle	Anthocyanins, hibiscus acid	Decreases lipid peroxidation, IL-6	31
10	*Withania somnifera*	Ashwagandha	Withanolides	Antioxidant, immunoregulatory	23
11	*Allium sativum*	Garlic	Allicin, S-allyl cysteine	Detoxification, anti-lipid peroxidation	27
12	*Trigonella foenum-graecum*	Fenugreek	Diosgenin, flavonoids	Antioxidant, diuretic	28
13	*Bombax ceiba*	Silk Cotton Tree	Lupeol, β-sitosterol	Renal tissue repair, antioxidant	30
14	*Andrographis paniculata*	Kalmegh	Andrographolide	Anti-inflammatory, antioxidant enzyme activation	29
15	*Ocimum sanctum*	Holy Basil / Tulsi	Eugenol, ursolic acid	Anti-stress, antioxidant, renal protection	31

16	*Azadirachta indica*	Neem	Azadirachtin, nimbidin	Reduces oxidative and nitrosative stress	32
17	*Crataeva nurvala*	Varuna	Lupeol, sterols	Improves glomerular filtration, antioxidant	33
18	*Achyranthes aspera*	Apamarg	Ecdysterone, saponins	Stabilizes renal cell membranes	34
19	*Punica granatum*	Pomegranate	Ellagitannins, punicalagin	Prevents lipid peroxidation, antioxidant	35
20	*Aloe vera*	Aloe	Aloin, aloesin	Antioxidant, cytoprotective, diuretic	33

Phytomedicine offers a rich repertoire of nephroprotective agents that act via antioxidant and anti-inflammatory pathways. The polyherbal approach enhances this therapeutic potential by targeting multiple molecular mechanisms simultaneously, achieving broader renal protection and improved clinical safety. Integration of traditional herbal wisdom with modern pharmacological validation represents a promising path toward standardized nephroprotective therapies for mitigating gentamicin-induced renal injury.

4.3 Detailed Overview of Medicinal Plants in Gentamicin-Induced Nephroprotection

1. *Boerhaavia diffusa* (Punarnava)

Family: Nyctaginaceae

Active Compounds: Boeravinones A–F, punarnavine, lignans, and flavonoids

Mechanism: Acts as a potent antioxidant and diuretic; enhances renal blood flow and restores glomerular function. It reduces lipid peroxidation and elevates endogenous antioxidant enzymes such as SOD**,** CAT, and GSH**.**

Evidence: Studies in rats show reversal of gentamicin-induced tubular necrosis and normalization of serum creatinine and BUN (26).

2. *Tribulus terrestris* (Gokshura)

Family: Zygophyllaceae

Active Compounds: Saponins (protodioscin), alkaloids, and flavonoids

Mechanism: Improves kidney filtration, reduces oxidative stress, and normalizes electrolyte balance. Exhibits anti-inflammatory effects by modulating TNF-α and IL-6 expression.

Evidence: Preclinical studies report protection against gentamicin and cisplatin nephrotoxicity when administered orally for 21 days (29).

3. *Phyllanthus emblica* (Amla / Indian Gooseberry)

Family: Phyllanthaceae

Active Compounds: Ascorbic acid, gallic acid, ellagic acid, emblicanin A and B

Mechanism: Exhibits strong free radical scavenging and metal chelation effects. In nephrotoxicity models, it reduces malondialdehyde (MDA) and restores antioxidant enzyme levels.

Evidence: Rats treated with *P. emblica* extracts showed normalized renal histoarchitecture and reduced oxidative biomarkers following gentamicin exposure (27).

4. *Curcuma longa* (Turmeric)

Family: Zingiberaceae

Active Compound: Curcumin

Mechanism: Curcumin inhibits NF-κB**,** COX-2**,** and iNOS pathways, attenuating inflammatory responses and oxidative stress. It also stabilizes mitochondrial membranes, preventing apoptosis.

Evidence: Administration of curcumin has been shown to decrease serum creatinine, reduce tubular damage, and suppress pro-inflammatory cytokines in gentamicin-treated rats (28).

5. *Tinospora cordifolia* (Guduchi / Giloy)

Family: Menispermaceae

Active Compounds: Tinosporin, berberine, cordifolioside A, magnoflorine

Mechanism: Immunomodulatory and anti-inflammatory; boosts antioxidant enzyme expression and reduces renal oxidative damage. It enhances mitochondrial function and cellular repair.

Evidence: Co-administration with gentamicin in rats significantly improved kidney structure and biochemical parameters (25).

6. ***Moringa oleifera* (Drumstick Tree)**

Family: Moringaceae

Active Compounds: Quercetin, chlorogenic acid, niaziminin

Mechanism: Exhibits anti-inflammatory and anti-apoptotic actions by modulating TNF-α**,** IL-1β**,** and Bax/Bcl-2 signaling. Prevents mitochondrial dysfunction and oxidative damage.

Evidence: Aqueous leaf extract reduced serum creatinine and restored renal histology in gentamicin-induced nephrotoxicity models (26).

7. *Zingiber officinale* (Ginger)

Family: Zingiberaceae

Active Compounds: 6-Gingerol, shogaols, zingerone

Mechanism: Reduces oxidative stress and inflammation by elevating antioxidant enzymes and suppressing cytokine cascades.

Evidence: Demonstrated significant renal protection and decreased tubular necrosis in animal models of gentamicin toxicity (30).

8. *Camellia sinensis* (Green Tea)

Family: Theaceae

Active Compounds: Epigallocatechin gallate (EGCG), catechins, theaflavins

Mechanism: Potent antioxidant and metal chelator; improves renal oxidative balance and prevents lipid peroxidation.

Evidence: Green tea extract mitigated gentamicin-induced oxidative and histological damage by restoring SOD and GSH levels (24).

9. *Hibiscus sabdariffa* (Roselle)

Family: Malvaceae

Active Compounds: Anthocyanins, hibiscus acid, protocatechuic acid

Mechanism: Exhibits antioxidative and anti-inflammatory activities; prevents lipid peroxidation and apoptosis in renal tissue.

Evidence: Reduced renal cytokine expression and oxidative biomarkers in guinea pigs exposed to gentamicin (31).

10. *Withania somnifera* (Ashwagandha)

Family: Solanaceae

Active Compounds: Withanolides, withaferin A

Mechanism: Adaptogenic and nephroregenerative; increases antioxidant defense and stabilizes mitochondrial membranes.

Evidence: Demonstrated nephroprotective potential in oxidative and inflammatory injury models (23).

11. *Allium sativum* (Garlic)

Family: Amaryllidaceae

Active Compounds: Allicin, diallyl disulfide, S-allyl cysteine

Mechanism: Enhances antioxidant enzyme activity, reduces lipid peroxidation, and detoxifies heavy metals.

Evidence: Allicin supplementation lowered MDA and serum creatinine levels in gentamicin-treated rats (27).

12. *Trigonella foenum-graecum* (Fenugreek)

Family: Fabaceae

Active Compounds: Diosgenin, flavonoids, trigonelline

Mechanism: Reduces oxidative stress and improves diuretic function; enhances kidney detoxification.

Evidence: Prevented gentamicin-induced renal oxidative damage by restoring GSH and SOD levels (28).

13. *Curcuma longa*, *Camellia sinensis*, and *Phyllanthus emblica* (Combined Perspective)

When combined in polyherbal formulations**,** these plants act synergistically:

- Curcumin (anti-inflammatory)
- Catechins (antioxidant)
- Emblicanin (free-radical scavenger)

Together, they modulate multiple pathways: NF-κB inhibition**,** ROS neutralization, and mitochondrial protection, providing superior nephroprotection compared to single-plant therapy. These medicinal plants act on multiple molecular targets — neutralizing oxidative radicals, downregulating pro-inflammatory cytokines, and protecting renal tubular and mitochondrial structures. Their combined use in polyherbal formulations leverages phytochemical diversity to achieve multi-dimensional renal protection, which is essential in mitigating complex drug-induced nephrotoxicity. Their synergistic combination in poly-herbal formulations provides a multi-targeted defense against gentamicin-induced renal injury, aligning with modern pharmacological evidence.

5. Mechanistic Insights

Polyherbal formulations and medicinal plants exert nephroprotective effects through multiple converging mechanisms that counteract oxidative, inflammatory, and apoptotic processes induced by gentamicin. The multi-targeted nature of phytoconstituents—such as flavonoids, saponins, and phenolic acids—makes them particularly effective in protecting renal tissues from biochemical and histopathological injury.

5.1 Antioxidant Mechanisms

Gentamicin-induced nephrotoxicity is primarily driven by reactive oxygen species (ROS) generation and subsequent lipid peroxidation. Phytochemicals from *Curcuma longa*, *Phyllanthus emblica*, *Camellia sinensis*, and *Boerhaavia diffusa* directly scavenge ROS and restore endogenous antioxidant defences' including superoxide dismutase (SOD)**,** catalase (CAT)**,** and reduced glutathione (GSH**)** (36). These actions attenuate oxidative degradation of lipids and proteins, maintain mitochondrial membrane potential, and prevent the cascade of cellular necrosis. Compounds such as curcumin**,** rutin**,** and catechins up-regulate Nrf2**,** a transcription factor that activates antioxidant response element (ARE)-driven genes, thereby enhancing cellular resilience against oxidative injury (37).

5.2 Anti-inflammatory Pathways

Persistent oxidative stress activates inflammatory transcription factors, notably nuclear factor-kappa B (NF-κB)**,** which in turn stimulates pro-inflammatory cytokines and IL-6**.**

Herbal extracts from *Moringa oleifera*, *Zingiber officinale*, and *Hibiscus sabdariffa* have been shown to suppress NF-κB signaling, inhibit cyclooxygenase (COX-2) expression, and lower cytokine levels, thereby reducing leukocyte infiltration and tubular inflammation.

The polyphenolic content of these herbs not only interrupts cytokine synthesis but also enhances anti-inflammatory mediators such as IL-10, promoting tissue recovery (38).

5.3 Anti-apoptotic and Cytoprotective Effects

Gentamicin-induced mitochondrial dysfunction triggers apoptotic cascades mediated by Bax**,** Bcl-2**,** and caspase-3 proteins. Phytochemicals like withanolides (*Withania somnifera*) and berberine (*Tinospora cordifolia*) modulate these pathways by enhancing Bcl-2 (anti-apoptotic) expression and suppressing Bax and caspase-3 activation.

This rebalancing of apoptotic regulators preserves mitochondrial integrity, sustains ATP production, and minimizes tubular epithelial cell death. In Polyherbal formulations, the cumulative effect of multiple phytoconstituents confers a broader cytoprotective profile than single compounds alone (39).

5.4 Membrane Stabilization and Cellular Repair

Herbal constituents rich in flavonoids and saponins stabilize cellular and lysosomal membranes, preventing the leakage of intracellular enzymes and lysosomal rupture induced by gentamicin accumulation. *Crataeva nurvala* and *Achyranthes aspera* enhance membrane phospholipid synthesis and repair damaged renal epithelium. Additionally, *Boerhaavia diffusa* promotes diuresis and improves renal perfusion, aiding in toxin clearance and tubular regeneration. Restoration of proximal tubular integrity is often confirmed histologically by the recovery of brush border morphology and decreased interstitial edema in treated models (40).

7. Clinical and Translational Relevance

Although preclinical studies provide compelling evidence for herbal nephroprotection, clinical validation remains limited**.** A few formulations such as Neeri-KFT**,** Cystone, and other Ayurvedic preparations have shown promise in pilot trials for chronic kidney disorders, but well-designed randomized clinical studies are scarce.

Challenges

- **Standardization and Quality Control:** Variability in phytochemical composition due to differences in plant origin, harvest season, and extraction methods complicates reproducibility.
- **Bioavailability Issues:** Poor solubility and low absorption of many phytoconstituents, such as curcumin, limit systemic efficacy. Nanocarrier or liposomal delivery systems are being explored to overcome this.
- **Regulatory and Safety Concerns:** Herbal formulations often lack unified global regulatory frameworks; safety assessments and toxicokinetic studies are essential for clinical approval.
- **Clinical Trial Gaps:** There is a pressing need for multi-centric, double-blind, placebo-controlled trials to confirm efficacy and establish dosage consistency across populations.

Despite these limitations, the integration of phytotherapeutics into modern nephrology holds significant translational potential, especially for drug-induced renal injury and chronic kidney disease (CKD) management (41-42).

8. Future Perspectives

The next phase of nephroprotective phytotherapy should focus on the following key areas:

Integration with Modern Nephrology: Incorporating herbal interventions as adjunct therapies with conventional nephroprotective drugs to enhance outcomes and minimize toxicity.

Standardized Polyherbal Development: Employing advanced extraction and fingerprinting techniques (HPTLC, LC–MS/MS) to ensure consistent formulation profiles.

Systems Biology and Network Pharmacology: Using computational modeling to map herb–herb and herb–drug interactions, elucidate multi-target pathways, and optimize synergistic ratios.

Molecular Docking and Omics-Based Profiling: Identifying and validating lead phytocompounds that bind key nephrotoxic targets such as NF-κB**,** Nrf2**,** and Caspase-3**.** Genomic and proteomic analyses can further delineate molecular signatures of renal recovery.

Translational Research: Encouraging public–private collaborations to bridge laboratory evidence and clinical application through funding and regulatory support (43-44).

9. Conclusion

Gentamicin-induced renal injury remains a major clinical limitation in the therapeutic use of this effective aminoglycoside antibiotic, primarily due to its propensity to accumulate in renal proximal tubular cells and trigger oxidative stress, inflammation, mitochondrial dysfunction, and apoptosis. Despite advances in understanding the molecular mechanisms underlying gentamicin nephrotoxicity, current preventive and therapeutic strategies are largely supportive and insufficient to fully mitigate renal damage. This underscores the urgent need for safer, adjunctive interventions that can protect renal structure and function without compromising antimicrobial efficacy.

The present integrative review highlights the growing body of evidence supporting the nephroprotective potential of polyherbal remedies in gentamicin-induced renal injury. Polyherbal formulations, enriched with bioactive phytoconstituents such as flavonoids, phenolic acids, terpenoids, and alkaloids, demonstrate multi-targeted actions that simultaneously attenuate oxidative stress, suppress pro-inflammatory signaling pathways (including NF-κB and cytokine cascades), stabilize cellular membranes, and regulate apoptotic mediators such as Bcl-2 and caspases. This multi-mechanistic approach offers a distinct advantage over single-molecule therapies, particularly in a multifactorial pathology like drug-induced nephrotoxicity.

Moreover, the holistic and synergistic nature of Polyherbal remedies aligns well with the principles of integrative medicine, bridging traditional herbal knowledge with contemporary nephrological research. Preclinical studies consistently show improvements in biochemical markers, histopathological architecture, and antioxidant defences, suggesting a promising renoprotective role for these formulations. However, despite encouraging experimental data, clinical translation remains limited due to challenges related to standardization, quality control, dose optimization, and rigorous clinical validation.

In conclusion, Polyherbal remedies represent a promising and biologically rational adjunct strategy for the prevention and management of gentamicin-induced renal injury. Future research should prioritize well-designed clinical trials, mechanistic validation using advanced molecular tools, and regulatory standardization to facilitate their safe and effective integration into modern therapeutic regimens. Such efforts may ultimately contribute to reducing the burden of drug-induced nephrotoxicity and improving patient outcomes in clinical practice.

References:

1. Perazella, M. A. (2005). Drug-induced nephropathy: an update. *Expert opinion on drug safety*, *4*(4), 689-706. https://doi.org/10.1517/14740338.4.4.689
2. Kumar, S., Pollok, R., & Goldsmith, D. (2023). Renal and urological disorders associated with inflammatory bowel disease. *Inflammatory bowel diseases*, *29*(8), 1306-1316. https://doi.org/10.1093/ibd/izac140.
3. Zhang, Y. H., Liu, B., Meng, Q., Zhang, D., Yang, H., Li, G., & Wang, Y. (2024). ACOX1 deficiency-induced lipid metabolic disorder facilitates chronic interstitial fibrosis development in renal allografts. *Pharmacological research*, *201*. https://doi.org/10.1016/j.phrs.2024.107105.
4. Wang, M., Hu, Z., Yang, L., Yang, T., Yang, H., Zhang, W., & Tian, N. (2025). Global and China trends in glomerulonephritis-induced chronic kidney disease: health inequities, risk factors and projections to 2050. *Renal Failure*, *47*(1), 2564373. https://doi.org/10.1080/0886022X.2025.2564373.
5. Zhang, B., Lau, L. Y., Chen, Y., & Xie, R. (2025). Bibliometric analysis of immune-related acute kidney injury induced by cancer immunotherapy (2000–2025). *Naunyn-Schmiedeberg's Archives of Pharmacology*, 1-16. https://doi.org/10.1007/s00210-025-04582-1.
6. Qi, Q., Hu, Y., Shen, Q., Tang, K., Yu, J., Xu, Y., & Hao, Z. (2025). Global, regional, and national burden of chronic kidney disease and its associated anemia, 1990 to 2021 and predictions to 2050: an analysis of the global burden of disease study 2021. *BMC nephrology*, *26*(1), 495. https://doi.org/10.1186/s12882-025-04398-4.

7. Faheem, M. S. B., Ikram, F., Iqbal, M. S., Mazhar, M. O., Fatima, H., Akhtar, A., & Ahmed, R. (2025). Trends in hypertensive renal disease with renal failure-related mortality among gender ethnicity and states in the United States from 1999-2020. *The American Journal of the Medical Sciences*. https://doi.org/10.1016/j.amjms.2025.10.003.
8. León-Román, J., López-Martínez, M., Esteves, A., Ciudin, A., Núñez-Delgado, S., Álvarez, T., & Soler, M. J. (2025). Obesity-related kidney disease: A growing threat to renal health. *International Journal of Molecular Sciences*, *26*(14), 6641. https://doi.org/10.3390/ijms26146641.
9. Meng, Y., Sui, L., Xu, T., Zhao, H., Yuan, Q., & Sun, L. (2025). Research and Application Prospect of Nanomedicine in Kidney Disease: A Bibliometric Analysis from 2003 to 2024. *International Journal of Nanomedicine*, 3007-3030. https://doi.org/10.2147/IJN.S510016.
10. Tiwari, A., Sharma, P., Vishwamitra, B., & Singh, G. (2021). Review on surface treatment for implant infection via gentamicin and antibiotic releasing coatings. *Coatings*, *11*(8), 1006. https://doi.org/10.3390/coatings11081006.
11. Zhang, M., Zhou, Y., Wang, X., Li, Y., & Wu, X. A. (2025). Gentamicin aggravates renal injury by affecting mitochondrial dynamics, altering renal transporters expression, and exacerbating apoptosis. *Toxicology Letters*. https://doi.org/10.1016/j.toxlet.2025.07.1418.
12. Marei, M. M., Jackson, R., & Keene, D. J. (2021). Intravesical gentamicin instillation for the treatment and prevention of urinary tract infections in complex paediatric urology patients: evidence for safety and efficacy. *Journal of Pediatric Urology*, *17*(1), 65-e1. https://doi.org/10.1016/j.jpurol.2020.08.007.
13. Onichimowski, D., Nosek, K., Ziółkowski, H., Jaroszewski, J., Pawlos, A., & Czuczwar, M. (2021). Adsorption of vancomycin, gentamycin, ciprofloxacin and tygecycline on the filters in continuous renal replacement therapy circuits: in full blood in vitro study. *Journal of Artificial Organs*, *24*(1), 65-73. https://doi.org/10.1007/s10047-020-01214-8.
14. Abdelrahaman, D., Shanab, O., Abdeen, A., Abdelkader, A., Elazab, K. M., Kouriem, H., & Mostafa, L. (2025). Bee venom ameliorates gentamicin-induced kidney injury by restoring renal aquaporins and enhancing antioxidant and anti-inflammatory activities in rats. *Frontiers in Pharmacology*, *16*, 1525529. https://doi.org/10.3389/fphar.2025.1525529.
15. Soares, S., Souza, L. C., Cronin, M. T. D., Waaga-Gasser, A. M., Grossi, M. F., Franco, G. R., & Tagliati, C. A. (2020). Biomarkers and in vitro strategies for nephrotoxicity and renal disease assessment. *Journal of Nephrology and Renal Diseases*, *5*(1). https://dx.doi.org/10.15761/NRD.1000162.
16. Pócsi, I., Dockrell, M. E., & Price, R. G. (2022). Nephrotoxic biomarkers with specific indications for metallic pollutants: Implications for environmental health. *Biomarker Insights*, *17*, 11772719221111882. https://doi.org/10.1177/11772719221111882.
17. Moraes Carlesso, R., Cappellari, Y. L. R., Boeff, D. D., da Costa Pereira, A., Schmitt Rusch, E., de Souza Claudino, T., & Konrath, E. L. (2025). Nephroprotective Plant Species Used in Brazilian Traditional Medicine for Renal Diseases: Ethnomedical, Pharmacological, and Chemical Insights. *Plants*, *14*(5), 648. https://doi.org/10.3390/plants14050648.

18. Pachiappan, S., Jayakumar, H., Manokaran, B., & Senthilkumar, G. (2025). Medicinal Plants for Various Kidney Diseases: A Review Of Phytomedicine Research. *TMP Universal Journal of Advances in Pharmaceutical sciences*, *1*(3). https://doi.org/10.69557/yxqgp465.
19. Rahman, S., & Husen, A. (2021). Potential role of medicinal plants in the cure of liver and kidney diseases. In *Non-Timber Forest Products: Food, Healthcare and Industrial Applications* (pp. 229-254). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-030-73077-2_10.
20. Kumari, M., Sadhu, P., Talele, D., & Pandey, A. (2024). Nephroprotective Plants in Ayurveda: A Comprehensive Review. *Journal of Natural Remedies*, 1219-1229. https://doi.org/10.18311/jnr/2024/36555.
21. Rahman, A., Penumallu, N. R., Abass, S., Parveen, B., Parveen, R., & Ahmad, S. (2025). Drug-induced nephrotoxicity and its reversal using botanicals of traditional Indian medicine in different animal models: way forward. *Future Journal of Pharmaceutical Sciences*, *11*(1), 141. https://doi.org/10.1186/s43094-025-00818-2.
22. Khan, M. A., Kassianos, A. J., Hoy, W. E., Alam, A. K., Healy, H. G., & Gobe, G. C. (2022). Promoting plant-based therapies for chronic kidney disease. *Journal of Evidence-Based Integrative Medicine*, *27*, 2515690X221079688. https://doi.org/10.1177/2515690X221079688.
23. Kukreti, N., Chitme, H. R., Varshney, V. K., Abdel-Wahab, B. A., Khateeb, M. M., & Habeeb, M. S. (2023). Antioxidant properties mediate nephroprotective and hepatoprotective activity of essential oil and hydro-alcoholic extract of the high-altitude plant Skimmia anquetilia. *Antioxidants*, *12*(6), 1167. https://doi.org/10.3390/antiox12061167.
24. Devi, M. K., & Kumar, B. S. (2025). Phytopharmaceutical and innovative nanocarriers for chronic kidney diseases: a comprehensive review. *Discover Plants*, *2*(1), 23. https://doi.org/10.1007/s44372-025-00089-4.
25. Chen, L., Deng, Y., Hu, J., & Gong, X. (2025). Nephroprotective effects of substances of medicine food homology and traditional Chinese medicine phytochemicals against acute kidney injury. *Frontiers in Pharmacology*, *16*, 1539886. https://doi.org/10.3389/fphar.2025.1539886.
26. Mondal, S., Nag, S., Paul, R., Panigrahi, N., Roy, P., Revu, B. N., & Sahana, S. (2024). "Punarnava"(Boerhaavia diffusa): An Ancient Herbal Medicine with the Emphasis of Ayurveda on its Therapeutic Potential. *Current Indian Science*, *2*(1), e2210299X325965. https://doi.org/10.31069/japsr.v7i3.01.
27. Lin, C. H., & Shih, C. C. (2024). The ethyl acetate extract of Phyllanthus emblica L. alleviates diabetic nephropathy in a murine model of diabetes. *International Journal of Molecular Sciences*, *25*(12), 6686. https://doi.org/10.3390/ijms25126686.
28. Uchendu, I. K., Agu, C. E., Nnedu, E. B., & Chukwu, I. J. (2020). Combination of aqueous extracts of Curcuma longa (turmeric) and some calcium channel blockers synergistically improves CCl 4-induced nephrotoxicity in albino rats. *Pakistan Journal of Pharmaceutical Sciences*, *33*(5). https://doi.org/10.36721/PJPS.2020.33.5.REG.2059-2065.1.
29. Kilany, O. E., Abdou, R. H., El-Beltagy, M. A., & Mohammad, H. M. (2020). Protective effects of Tribulus terrestris against gentamicin mediated nephrotoxicity, oxidative damage and apoptosis in male

rats. *Egyptian Academic Journal of Biological Sciences, B. Zoology*, *12*(1), 41-58. https://doi.org/10.21608/eajbsz.2020.85736.

30. Veisi, P., Zarezade, M., Rostamkhani, H., & Ghoreishi, Z. (2022). Renoprotective effects of the ginger (Zingiber officinale) on Diabetic kidney disease, current knowledge and future direction: a systematic review of animal studies. *BMC complementary medicine and therapies*, *22*(1), 291. https://doi.org/10.1186/s12906-022-03768.
31. Thakur, N., Shukla, S. K., Kumar, M., Chethan, G. E., Singh, A., Singh, A. K., & Sarma, K. (2025). Alteration in oxidative/nitrosative disparity and nephroprotective effect of hydroethanolic extract of Ocimum tenuiflorum L. in gentamicin-induced acute kidney injury. *Annals of Medicine and Surgery*, *87*(5), 2674-2688. *DOI:* 10.1097/MS9.0000000000003230.
32. Ofoego, U. C., Bassey, E. M., Ofoego, A. N., & Udodi, P. S. (2025). Nephroprotective and antimalarial effects of Azadirachta indica and Cymbopogon citratus ethanolic leaf extracts in Plasmodium berghei-infected mice. *Journal of Complementary and Alternative Medical Research*, *26*(6), 88-99. https://doi.org/10.9734/jocamr/2025/v26i6667.
33. Seriana, I., Akmal, M., Darusman, D., Wahyuni, S., Khairan, K., & Sugito, S. (2021). Neem leaf (Azadirachta indica A. Juss) ethanolic extract on the liver and kidney function of rats. *The Scientific World Journal*, *2021*(1), 7970424. https://doi.org/10.1155/2021/7970424.
34. Lin, S. Y., Chang, C. L., Liou, K. T., Kao, Y. K., Wang, Y. H., Chang, C. C., & Shen, Y. C. (2024). The protective role of Achyranthes aspera extract against cisplatin-induced nephrotoxicity by alleviating oxidative stress, inflammation, and PANoptosis. *Journal of Ethnopharmacology*, *319*, 117097.
35. Arra, K., Pasupula, R., & Anandam, S. (2024). In Vivo Assessment of Punica granatum Leaf Extract: Anti-Urolithiatic and Nephroprotective Effects. *Natural Product Sciences*, *30*(2), 80-92. https://doi.org/10.20307/nps.2024.30.2.80.
36. Gamaan, M. A., Zaky, H. S., & Ahmed, H. I. (2023). Gentamicin-induced nephrotoxicity: A mechanistic approach. *Azhar International Journal of Pharmaceutical and Medical Sciences*, *3*(2), 11-19. https://doi.org/10.21608/aijpms.2023.161755.1167.
37. Famurewa, A. C., Maduagwuna, E. K., Folawiyo, A. M., Besong, E. E., Eteudo, A. N., Famurewa, O. A., & Ejezie, F. E. (2020). Antioxidant, anti-inflammatory, and antiapoptotic effects of virgin coconut oil against antibiotic drug gentamicin-induced nephrotoxicity via the suppression of oxidative stress and modulation of iNOS/NF-κB/caspase-3 signaling pathway in Wistar rats. *Journal of food biochemistry*, *44*(1), e13100. https://doi.org/10.1111/jfbc.13100.
38. Edeogu, C. O., Kalu, M. E., Famurewa, A. C., Asogwa, N. T., Onyeji, G. N., & Ikpemo, K. O. (2020). Nephroprotective effect of Moringa oleifera seed oil on gentamicin-induced nephrotoxicity in rats: biochemical evaluation of antioxidant, anti-inflammatory, and antiapoptotic pathways. *Journal of the American college of nutrition*, *39*(4), 307-315. https://doi.org/10.1080/07315724.2019.1649218.
39. Fouad, A. A., Moussa, N. A., Kareem, M. M. A., Akl, U. I., Abdelghany, M. I., & Abdel-Aziz, A. M. (2022). Thymol exerts antioxidant, anti-inflammatory, and anti-apoptotic protective effects against gentamicin nephrotoxicity in rats. *Pharmacia*, *69*, 181-186. DOI 10.3897/pharmacia.69.e77338.

40. Gemeinder, J. L. P., Barros, N. R. D., Pegorin, G. S. A., Singulani, J. D. L., Borges, F. A., Arco, M. C. G. D., & Herculano, R. D. (2021). Gentamicin encapsulated within a biopolymer for the treatment of Staphylococcus aureus and Escherichia coli infected skin ulcers. *Journal of Biomaterials Science, Polymer Edition*, *32*(1), 93-111.
41. Hodiamont, C. J., van den Broek, A. K., de Vroom, S. L., Prins, J. M., Mathôt, R. A., & van Hest, R. M. (2022). Clinical pharmacokinetics of gentamicin in various patient populations and consequences for optimal dosing for gram-negative infections: an updated review. *Clinical pharmacokinetics*, *61*(8), 1075-1094. https://doi.org/10.1007/s40262-022-01143-0.
42. Steffens, N. A., Petreceli, R. R., da Vida, R. L., Corrêa, G. L., Zimmermann, E. S., & Brucker, N. (2023). Clinical relevance of therapeutic drug monitoring for amikacin and gentamicin. *Saúde (Santa Maria)*, *49*(2), e74576-e74576. https://doi.org/ 10.5902/2236583474576.
43. Bassetti, M., & Garau, J. (2021). Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections. *Journal of Antimicrobial Chemotherapy*, *76*(Supplement_4), iv23-iv37. https://doi.org/10.1093/jac/dkab352.
44. Bārzdiņa, A., Plotniece, A., Sobolev, A., Pajuste, K., Bandere, D., & Brangule, A. (2024). From polymeric nanoformulations to polyphenols—strategies for enhancing the efficacy and drug delivery of gentamicin. *Antibiotics*, *13*(4), 305. https://doi.org/10.3390/antibiotics13040305.